| __timestamp | ACADIA Pharmaceuticals Inc. | Alnylam Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 32748000 | 44526000 |
| Thursday, January 1, 2015 | 90804000 | 60610000 |
| Friday, January 1, 2016 | 186456000 | 89354000 |
| Sunday, January 1, 2017 | 255062000 | 199365000 |
| Monday, January 1, 2018 | 265758000 | 382359000 |
| Tuesday, January 1, 2019 | 325638000 | 479005000 |
| Wednesday, January 1, 2020 | 388661000 | 588420000 |
| Friday, January 1, 2021 | 396028000 | 620639000 |
| Saturday, January 1, 2022 | 369090000 | 770658000 |
| Sunday, January 1, 2023 | 402466000 | 795646000 |
| Monday, January 1, 2024 | 975526000 |
Data in motion
In the competitive landscape of biopharmaceuticals, understanding the efficiency of Selling, General, and Administrative (SG&A) expenses is crucial. Over the past decade, Alnylam Pharmaceuticals, Inc. and ACADIA Pharmaceuticals Inc. have shown distinct trajectories in their SG&A spending. From 2014 to 2023, Alnylam's SG&A expenses surged by approximately 1,700%, reflecting its aggressive expansion and investment in innovation. In contrast, ACADIA's expenses grew by about 1,130%, indicating a more measured approach.
This analysis highlights the strategic differences in managing operational costs, with Alnylam focusing on rapid growth and ACADIA on sustainable scaling.
Operational Costs Compared: SG&A Analysis of Gilead Sciences, Inc. and ACADIA Pharmaceuticals Inc.
Regeneron Pharmaceuticals, Inc. or Alnylam Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Takeda Pharmaceutical Company Limited and Alnylam Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for argenx SE and ACADIA Pharmaceuticals Inc.
Cost Management Insights: SG&A Expenses for Alnylam Pharmaceuticals, Inc. and BioMarin Pharmaceutical Inc.
Alnylam Pharmaceuticals, Inc. or Viking Therapeutics, Inc.: Who Manages SG&A Costs Better?
Breaking Down SG&A Expenses: Alnylam Pharmaceuticals, Inc. vs Apellis Pharmaceuticals, Inc.
R&D Spending Showdown: Alnylam Pharmaceuticals, Inc. vs ACADIA Pharmaceuticals Inc.
Cost Management Insights: SG&A Expenses for Alnylam Pharmaceuticals, Inc. and Merus N.V.
Operational Costs Compared: SG&A Analysis of Alnylam Pharmaceuticals, Inc. and Iovance Biotherapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Alnylam Pharmaceuticals, Inc. and MannKind Corporation
Comparing SG&A Expenses: ACADIA Pharmaceuticals Inc. vs Viridian Therapeutics, Inc. Trends and Insights